The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Eli Lilly ( LLY 0.91%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...

Madison Investments, an investment advisor, released its “Madison Sustainable Equity Fund” third quarter 2024 investor letter ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Eli Lilly now ranks as the largest drugmaker in the world based ... Much of Lilly's recent dismal stock performance stems ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

On Friday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $746.2 which represents a decrease of $-40.03 or -5.09% from the prior close of $786.23. The stock opened at $775.19 and ...

Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...

Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...